NCT01541943View on ClinicalTrials.gov

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Essential HypertensionHyperlipidemia
Interventions
DRUG

Atorvastatin

Once daily, administered orally, 8 week

DRUG

Losartan

Once daily, administered orally, 8 week

DRUG

Placebo

Once daily, administered orally, 8 week

DRUG

HL-040XC

Once daily, administered orally, 8 week

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HanAll BioPharma Co., Ltd.

INDUSTRY

NCT01541943 - Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia | Biotech Hunter | Biotech Hunter